Latest Expert Opinions

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
December 19, 2018
It has always been too expensive for him. Maybe they have built out too many stores, but it has had a hard time continuing to justify valuations.
Show full opinionHide full opinion
Starbucks (SBUX-Q)
December 19, 2018
It has always been too expensive for him. Maybe they have built out too many stores, but it has had a hard time continuing to justify valuations.
HOLD
HOLD
December 19, 2018
Health insurer in the US. With Obama Care, it is hard to know if it will be repealed or not. A good company, trading at reasonable valuations.
Show full opinionHide full opinion
Anthem Inc (ANTM-N)
December 19, 2018
Health insurer in the US. With Obama Care, it is hard to know if it will be repealed or not. A good company, trading at reasonable valuations.
DON'T BUY
DON'T BUY
December 19, 2018
They try to manage their P&L well to earn a 7-9% earnings growth rate and the yields have competed well against bonds. He is hesitant on this space, because society has evolved away from buying branded products that can be 50% more expensive.
Show full opinionHide full opinion
Procter & Gamble (PG-N)
December 19, 2018
They try to manage their P&L well to earn a 7-9% earnings growth rate and the yields have competed well against bonds. He is hesitant on this space, because society has evolved away from buying branded products that can be 50% more expensive.
COMMENT
COMMENT
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
Show full opinionHide full opinion
CVS Health Corp (CVS-N)
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
COMMENT
COMMENT
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
Show full opinionHide full opinion
Bank of America (BAC-N)
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
DON'T BUY
DON'T BUY
December 19, 2018
It is hard to not be excited about their new technology in payment systems. His concern is paying 9 times revenue -- hugely expensive, he thinks. Maybe it stands the test of time, but he will pass at this level.
Show full opinionHide full opinion
Square Inc (SQ-N)
December 19, 2018
It is hard to not be excited about their new technology in payment systems. His concern is paying 9 times revenue -- hugely expensive, he thinks. Maybe it stands the test of time, but he will pass at this level.
DON'T BUY
DON'T BUY
December 19, 2018
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
December 19, 2018
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.